The European preventive inhaler market was valued at around $2.8 billion in 2018 and is anticipated to grow at a substantial rate of 1.5% during the forecast period. Major countries that will contribute to the inhaler market within the region includes UK, Germany, France, Italy and Spain. A significant number of companies, research, patient base has been observed in the market due to which a significant growth can be observed in the market. According to the International Monetary Fund (IMF), Europe is home to around 740 million people and the GDP of the European Union is $19.7 trillion in 2017. As per Organization for Economic Co-operation and Development (OECD), the self-reported asthma rate and COPD rate by European Union countries were 6.1% and 4.0% respectively and it has been found out that the rate of prevalence of diseases are higher in women as compared to men. This is expected to drive the regional business growth of the preventive inhaler market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/european-preventive-inhaler-market
The European preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of device, the market is sub-segmented into metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have the largest market share in the European preventive inhaler market due to providing an easy inhalation solution. Whereas, the market for metered dose inhaler is estimated to be the fastest-growing at a CAGR during the forecast period owing to innovations and collaborations by the companies for the development of metered dosed inhaler. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/european-preventive-inhaler-market
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing inhalers to cater to a wide range of customers within the region and across the globe. The major players of the European preventive inhaler market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., Koninklijke Philips N.V., and Bespak. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Market Segmentation
European Preventive Inhaler Market by Device Type
- Metered Dose Inhaler
- Dry Powder Inhaler
European Preventive Inhaler Market by Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
European Preventive Inhaler Market by End-User
- Homecare
- Hospitals and Clinics
Regional Analysis
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- AstraZeneca PLC
- Bespak
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici S.P.A.
- GF Health
- GlaxoSmithKline PLC
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Pulmatrix Inc.
- Savara, Inc.
- Teicos Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Vitalograph Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
